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aPTT; activated partial thromboplastin time 
Ca2+; ionized calcium 
CRF; case report form 
fT3; free triiodothyronine 
fT4; free thyroxine 
Hgb; hemoglubin 
Ht; hematocrit 
ICF; Informed consent form 
INR; International normalized ratio 
P+; phosphorus 
PT; prothrombin time 
PTH; parathormone 
TSH; thyroid stimulating hormone 
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This is a prospective, randomized, double- blinded, single center clinical 
trial to evaluate the efficacy of Lugol's iodide solution in the 
management of intraoperative bleeding in patients with toxic 
multinodular goiter undergoing total thyroidectomy. The primary 
objective is to assess any difference in the amount of intraoperative 
bleeding in patients who receive preoperative Lugol’s iodine before total 
thyroidectomy. The secondary objectives are to assess any adverse 
events of the agent, to evaluate the effect of other cofactors on 
intraoperative bleeding during total thyroidectomy, as well as the 
changes in thyroid ultrasound measurements after 10days therapy with 
Lugol's solution. 27 patients will participate in the study, separated into 
two groups: Group A will receive Lugol's solution, Group b will receive 
placebo. The study will be conducted until all subjects of each category 
will have included. It is estimated that it will take up to 24 months to 
enroll the patients. The study duration for a single patient will be 15 
days. A per protocol analysis will be conducted initially.  
 
Keywords:  Lugol's solution, toxic multinodular goiter, total 
thyroidectomy, clinical study 
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1.0   Synopsis 
Study title: A prospective, randomized, double- blinded, single center 
clinical trial to evaluate the efficacy of Lugol's iodide solution in the 
management of intraoperative bleeding in patients with toxic 
multinodular goiter undergoing total thyroidectomy. 
Investigator:  Angeliki Chorti, MD 
Objective: The primary objective is to assess any difference in the 
amount of intraoperative bleeding between patients who receive 
preoperative Lugol’s iodine before total thyroidectomy due to toxic 
multinodular goiter and these who do not. The secondary objectives are 
to assess any adverse events of the agent as well as to evaluate the 
effect of other cofactors on intraoperative bleeding during total 
thyroidectomy. 
Population/ Sample size: 27 patients separated into two groups: Group A 
will receive Lugol's solution, Group b will receive placebo solution.  
Inclusion/ Exclusion Criteria:  
Inclusion criteria 
1) Patients are over 18 years old 
2) Patients scheduled for a non-emergency operation 
3) Patients diagnosed with toxic multinodular goiter 
4) Patients with pre- and postoperative parathormone (PTH), total serum 
calcium (corrected for albumin), phosphate levels within normal range.  
5) Patient signs and dates a written informed consent form (ICF) and indicates 
an understanding of the study procedures 
 
 Exclusion criteria  
1) Patient is participating in another clinical trial which may affect this 
study’s outcomes 
2) Patient with solitary toxic nodule  
3) Patients with non-toxic multinodular goiter 
4) Patient with uncertain fine-needle aspiration biopsy (indicating cancer 
or suspicious cytology)  
5) Patient with previous thyroid and parathyroid operation or neck 
irradiation 
6) Patients with retrosternal multinodular goiter 
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7) Patients with recurrence of multinodular goiter  
8) Pregnancy   
9) Refusal to participate in the study 
10) Patient receiving anticoagulation treatment for other medical condition 
11) Systemic diseases (e.g. infections, neoplasms, coagulation disorders) 
 
Design: This study is an open, prospective, randomized, double- blinded, 
placebo controlled single center clinical study to evaluate the efficacy of 
Lugol's solution in the management of intraoperative bleeding during 
total thyroidectomy in patients with multinodular goiter.  
Duration: The study will be conducted until all subjects of each category 
will have included. It is estimated that it will take up to 24 months to 
enroll the patients. The study duration for a single patient will be 15 
days. 
Data analysis: In this study, the primary analysis will be conducted 
according to per protocol analysis method. 
Endpoints: In this study, the primary endpoint is the assessment of 
minimized intraoperative bleeding during total thyroidectomy in patients 
with toxic multinodular goiter after receiving Lugol's solution compared 
to the placebo group. The secondary outcomes are the changes in 
thyroid ultrasound measurements after 10days therapy with Lugol's 
solution, as well as the assessment of possible confounding factors that 
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3.0   Background  
Hyperthyroidism is a condition of excessive production and secretion of 
thyroid hormones, which can lead to hemodynamic variations such as 
increased heart rate and  myocardial contractility and decreased 
peripheral resistance. The preoperative preparation of these patients is 
of great importance in order that severe intraoperative and 
postoperative complications, caused by the increased vascularity of the 
thyroid gland, are avoided. One of the most serious complications is the 
postoperative bleeding into the neck which can be life-threatening as it 
can threaten the airway. The percentage of this complication is low in 
experienced hands (0.25-2.3%). Furthermore, an  increased 
intraoperative bleeding can reduce the surgeon's ability to detect the 
recurrent laryngeal nerve, the other vessels of the neck and the 
parathyroid glands. [1] 
 Preoperative treatment with Lugol solution before total thyroidectomy 
is a new method of reducing the intraoperative bleeding as well as the 
complications caused by increased vascularity of the gland. Lugol 
solution is a solution of inorganic iodine, potassium iodide and distilled 
water which increase the thyroid iodide uptake, blocks the synthesis and 
secretion of thyroid hormones (causing an acute Wolff- Chaikoff effect) 
and reduces the vascularization of the gland.[1-4] Although its use is 
widespread as an antithyroid agent, there are not enough data for the 
effectiveness of the method, mainly due to lack of subjective assessment 
of the method. In addition to this, the drug dosage and the appropriate 
antithyroid therapy are still controversial in the international literature. 
According to ATA guidelines, the recommended dosage of Lugol's 
solution is 5-7 drops (meaning 0.25-0.35 ml, 8mg iodide/drop) three 
times per day mixed with water or juice for 10 days. [5, 6] 
Drug interactions [7]   
 antithyroid agents -- potentiate the hypothyroid and goitrogenic 
effects  
 captopril, enalapril, lisinopril -- causing hyperkalemia 
 lithium-- potentiate the hypothyroid and goitrogenic effects 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 16:34:33 EEST - 137.108.70.13
11 
 
 diuretics-- causing hyperkalemia 
 sodium-iodide 131(therapeutic)-- reduces the uptake of this agent  
Adverse events[7] 
 Allergic reactions (angioedema, arthralgia, eosinophilia, swelling 
of lymph nodes, urticaria) -- need medical attention, less frequent 
incidence[8] 
 Potassium toxicity-- need medical attention, less frequent 
incidence 
 Iodism-- need medical attention, less frequent incidence 
 diarrhea -- need medical attention if persistent, less frequent 
incidence 
 nausea, vomiting-- need medical attention if peristent, less 
frequent incidence[8] 
 stomach pain-- need medical attention if persistent, less frequent 
incidence 
 saliva swelling, increase in salivation, metallic taste of mouth 
 rash[8] 
 Jod- Basedow effect, due to prolongation of therapy [9] 
 
Precautions[7] 
 pregnancy- iodide cross the placenta and can cause thyroid 
dysfunction in the infant 
 Breast-feeding- iodide is distributed into the milk 
 Geriatrics- many co morbidities that should taken into 
consideration, especially renal dysfunction 
 Pediatrics-- may cause skin rash 
 
Color Doppler examination is the most reliable, non-invasive imaging 
technique of the preoperative assessment of the thyroid gland vascularity. 
Doppler is applied for the measurement of intrathyroidal blood flow as well 
as this of the main thyroid arteries.[4, 10] 
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4.0   Study objectives 
4.1 Primary objective 
To assess any difference in the amount of intraoperative bleeding 
between patients who receive preoperative Lugol’s iodine before 
total thyroidectomy due to toxic multinodular goiter and these who 
do not. 
4.2 Secondary objective 
To assess any adverse events of the agent. To evaluate the effect of 
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5.0 Study Design 
5.1 Overview 
This study is an open, prospective, randomized, double- blinded, placebo 
controlled single center clinical study to evaluate the efficacy of Lugol's 
solution in the management of intraoperative bleeding during total 
thyroidectomy in patients with multinodular goiter.  
5.2 Study duration 
The study will be conducted until all subjects of each category will have 
included. It is estimated that it will take up to 24 months to enroll the 
patients. The study duration for a single patient will be 15 days. 
5.3 Randomization method 
A simple randomization method will be applied in this study. During the 
initial visit, every patient will receive a  serial number which will be 
recorded on the Case Report Form (CRF) . This number will be unique 
and specific for this subject and will not be reassigned to another 
patient. The patients will be randomly assigned to the two groups in a 
1:1 ratio by  a certified computer system tested by our statisticians.  
5.4 Control and design 
Lugol's iodide is a solution administered orally with drops. The study 
drugs include Lugol's solution and placebo solution. They will be stored 
in a tight container in a dry place between 15-30°C. The placebo drug 
will be manufactured identical to the Lugol's solution by a specialized 
pharmacist and it will be preserved by the  sponsor in order that the 
solution administered will be unknown to the investigators.  
5.5 Blinding 
As this study is double- blinded, the two solutions will be identical (as 
mentioned above) in order that both the patients and the investigators 
do not know the drug administered.   
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6.0 Study population 
6.1 Inclusion criteria 
1) Patients are over 18 years old 
2) Patients scheduled for a non-emergency operation 
3) Patients diagnosed with toxic multinodular goiter 
4) Patients with pre- and postoperative parathormone (PTH), total 
serum calcium (corrected for albumin), phosphate levels within normal 
range.  
5) Patient signs and dates a written informed consent form (ICF) and 
indicates an understanding of the study procedures 
 
6.2 Exclusion criteria  
1) Patient is participating in another clinical trial which may affect this 
study’s outcomes 
2) Patient with solitary toxic nodule  
3) Patients with non-toxic multinodular goiter 
4) Patient with uncertain fine-needle aspiration biopsy (indicating 
cancer or suspicious cytology)  
5) Patient with previous thyroid and parathyroid operation or neck 
irradiation 
6) Patients with retrosternal multinodular goiter 
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7) Patients with recurrence of multinodular goiter  
8) Pregnancy   
9) Refusal to participate in the study 
10) Patient receiving anticoagulation treatment for other medical 
condition 
11) Systemic diseases (e.g. infections, neoplasms, coagulation 
disorders) 
 
6.3 Withdrawal criteria 
As it is described in the informed consent form, any patient can 
withdraw from the study at any time without having any personal or 
medical cost.  
The withdrawal percentage should not exceed 10% , as a per protocol 
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7.0 Study Procedure 
Patients with toxic multinodular goiter that have an indication for 
surgery meeting the inclusion criteria will participate in this study after 
signing the inform consent form at the initial visit. Afterwards, patients 
will receive their unique serial number and will be randomly assigned to 
either Group A( Lugol Group) or Group B ( placebo group). The solution 
will be administered to the participants ten (10) days before surgery. 
Patients will be strongly advised to take 5 drops of the solution three 
times per day for 10 days. An ultrasound will be conducted at the initial 
visit and at day 9 after the drug administration in order that the volume 
of the thyroid gland and its blood supply to be measured. The 
ultrasound measurements will include the superior thyroid artery blood 
flow, resistance index and the thyroid gland volume. After the end of 10-
days Lugol treatment, patients will be operated, undergoing total 
thyroidectomy, by the same surgeon. Intraoperatively, the blood loss 
will be measured as the amount of blood in the suction bottle.  
7.1 Pre-operative measurements 
Procedures performed such as routine hospital examinations, antibiotic 
prophylactic treatment and diet will be according to the standard 
management protocol and will be recorded for the study. The following 
pre-surgery information will be recorded: 
1 Demographic information including: name, age, gender, ethnicity 
2 Height, weight, BMI and American Society of Anesthesiologists 
physical status classification system (I-VI) 
3 Behavioral history (Smoking, alcohol or drug use) 
4 Preoperative labs (WBC, Ht, Hgb, Ca2+, fT3, fT4, TSH, PTH, P+, PT, 
aPTT, INR)  
5 Diagnosis including clinical observations and previous imaging 
results 
6 Pre-operative ultra-sound characteristics of the thyroid gland 
(thyroid volume, blood flow, resistance index) 
Institutional Repository - Library & Information Centre - University of Thessaly




8 Current and past history of surgical and medical comorbidities 
9          Any adverse events related to the solution administered 
 
7.2  Intra-operative measurements 
The surgeon will perform the preplanned operation. The following 
intraoperative variables will be recorded for all patients: 
1 Surgery date 
2 Duration of surgery 
3 Operation performed 
4 The amount of blood in the suction bottle 
5 Procedure related comments 
 
7.3 Pathology data form 
The following pathology data will be recorded for all patients: 
1 Post-operative diagnosis including pathology report 
2 Weight of the thyroid gland 
3 Dimensions of the thyroid gland 
7.4 Postoperative measurements 
Follow-up evaluation will be performed during hospitalization.  The 
following information will be recorded: 
1 Postoperative labs (WBC, Ht, Hgb, Ca2+, fT3, fT4, TSH, PTH, P+, PT, 
aPTT, INR) 
2 Postoperative assessment of Chvostek and Trousseau signs 
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8.0 Complications and adverse events- discontinuation 
criteria 
Adverse events can be any unpleasant, unintended reaction, symptom, 
diagnosis, vital signs, deterioration of  any previous co morbidity, 
abnormal laboratory finding recorded at the initiation of the study or 
any new clinical manifestation that started coincidentally with the 
initiation of the study.  
Serious Adverse Events include: 
1 Death regardless of cause 
2 Any-life-threatening event 
3 Any hospitalization or prolongation of existing hospitalization 
4 Any event that results in persistent or significant disability or 
incapacity to the patient. 
Adverse reaction can be any unpleasant, unintended reaction to the 
investigational product related to the administered dose. An adverse 
reaction must be characterized by authorized medical expert as relevant 
(result of drug administration) or irrelevant (derives from a patient co 
morbidity)  to the drug. Their classification as mild, moderate and severe 
is based on the extent of daily activities limitations.  
Adverse events and reactions must be recorded in the CRF in a detailed 
way (what kind of event, when it started, its symptoms, the severity, the 
duration, if they occur prior to the initiation of the study).  Sponsor must 
be informed for an adverse experience within 24 hours and it should be 
included in the security report of the drug. Investigators are obliged to 
keep all the security reports for specific time defined by the local 
regulatory authorities. Patients should be followed-up after an adverse 
experience until recession or stabilization, including cases of patients 
withdrawn from the study.  
Study discontinuation criteria include safety, effectiveness and quality 
concerns about the drug administered. The sponsor can stop the clinical 
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study at any time, if there are  severe concerns, by a written termination 
report reporting the reasons of the study discontinuation. If an 
investigator intent to withdraw from the study, he/she must inform the 
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9.0 Statistical analysis 
9.1 Endpoints 
In this study, the primary endpoint is the assessment of minimized 
intraoperative bleeding during total thyroidectomy in patients with toxic 
multinodular goiter after receiving Lugol's solution compared to the 
placebo group. The mean difference of blood loss volume between the 
two groups will be compared. 
The secondary outcomes are the changes (mean difference) in thyroid 
ultrasound measurements (the superior thyroid artery blood flow, 
resistance index and the thyroid gland volume) after 10days therapy 
with Lugol's solution, as well as the assessment of possible confounding 
factors that affect the intraoperative bleeding. 
9.2 Sample size  
A power approach for two independent groups (means) will be applied 
for the sample size calculation in this clinical study. The power is set at 
90% and the p-value at 0.05.  According to literature, the mean blood 
loss volume in placebo group is μ1= 172.2 ml and SD= 96.2. A decrease in 
Lugol group of 50% ( μ2=86.1) is considered clinical significant. The 
sample size is estimated to be 27 patients.  
9.3 Data analysis 
The primary analysis will be conducted according to per protocol 
analysis.  
Parametrical Independent T-test or Mann-Whitney U test will be applied 
to check the null hypothesis that the intraoperative blood loss is equal 
between two treatment groups (Lugol and placebo). Furthermore, the 
difference between ultrasound findings before and after the use of 
Lugol's solution will be assessed with parametrical paired- sample t-test 
or Wilcoxon test. Chi-square test or Fisher's exact test will be applied for 
categorical variables. Logistic regression will be performed to assess the  
confounding factors for intraoperative bleeding (age, gender, ethnicity, 
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thyroid hormones' levels, Lugol's use, preoperative thyroid volume, 
blood flow).  
10.0 Data monitoring plan 
The monitoring of the data will be accrual. All records related to the 
study will be kept by the investigator ,who will be responsible for them 
until the completion  of the study. Afterwards, they will be transferred 
and stored in the general archive according to standards of good clinical 
practice. 
The progress of the clinical study will be under strict supervision by the 
sponsor. The sponsor will be responsible for the compliance, the 
integrity , coherence and reliability of the data and must have access to 
medical files.  The investigators must have frequent communication with 
the sponsor and inform them about all updates referring to the study. 
11.0 Human subjects- Data confidentiality 
11.1 Informed consent form 
Prior to study institution review board (IRB) approval should be 
obtained. Any changes in the study protocol, informed consent forms, or 
investigator must be re-approved by the IRB. All patients enrolled in the 
study will provide their consent prior to entering the study. An informed 
consent form shall be signed and dated by the patient. The investigator 
will retain the forms as part of the study records. 
This study will be executed in accordance with the Declaration of 
Helsinki, in agreement with the guidelines for conducting a clinical 
investigation in accordance with the principles of ICH GCP outlined in the 
E6 document. By signing the present protocol, participants in the study 
commit themselves to carry it out in accordance with local legal 
requirements. 
All eligible patients should have the capacity to provide an informed 
consent. The above described inclusion and exclusion criteria were 
designed to ensure the entry of the appropriate population of patients 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 16:34:33 EEST - 137.108.70.13
22 
 
to this study and will be approved by the local IRB. Screening for these 
criteria will be conducted by the coordinator. Eligible patients will be 
educated about the research proposal by a study investigator. To 
determine whether the patient has understood the issues, he/she will be 
asked to describe what the research entails and whether they have any 
questions. All questions will be addressed prior to enrollment. The 
patient can refuse participation in the study at any time. A written 
informed consent form will be generated. For each patient, a case report 
form (CRF) will be completed, providing general medical information and 
history. 
11.2 Data confidentiality  
Each patient will be identified by his/her initials and a unique patient 
identification number. Source data will be stored with source 
documents. Only personnel responsible for collecting data and 
transcribing it into the case report forms will have access to the data. 
Records will remain on site in secure areas. 
 
 
12.0 Publication Policy 
The results of this study will be reviewed by the investigators and the 
sponsors for a publication. The results will not be announced to another 




No additional funding for the execution of the present protocol is 
necessary. The investigators are willing to execute the present study 
without any additional reimbursement. 
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